ArticleJournal of ovarian research2026
Low muscle mass predicts poor response to neoadjuvant chemotherapy in advanced ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced epithelial ovarian cancer (EOC) is commonly diagnosed at late stages, and despite improvements with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS), prognosis remains poor. Body composition has emerged as an important determinant of treatment outcomes. Low muscle mass (LMM), particularly in obese patients with low muscle mass (OwLMM), may combine impaired functional reserve with adverse metabolic effects. However, its role in NACT outcomes in EOC remains unclear.
methodsIn this retrospective study, 52 overweight or obese women with FIGO stage III-IV EOC treated with platinum-taxane-based NACT and IDS between 2019 and 2022 were analyzed. Skeletal muscle mass was assessed on baseline computed tomography scans at the third lumbar vertebra (L3), and the lumbar skeletal muscle index (LSMI) was calculated. Patients were classified as LMM or high muscle mass (HMM) using the cohort median cut-off. Patients with both obesity and LMM were categorized as OwLMM. Treatment response was evaluated using RECIST v1.1 criteria.
resultsThe median follow-up was 10.2 months (95% CI, 7.8-12.6). Median disease-free survival (DFS) from IDS was 19.3 months (95% CI, 8.5-30.1). OwLMM patients had lower objective response rates (46.7% vs. 62.2%, p = 0.02) and inferior disease control rates (80% vs. 100%, p = 0.03) compared with other groups. BMI or LMM alone showed no significant effect. Overall survival (OS) analysis was premature due to the short follow-up period.
conclusionLow muscle mass, especially when combined with obesity, was associated with reduced NACT response and inferior disease control in advanced EOC. As sarcopenic obesity represents a key component of frailty in older adults, our findings support muscle mass assessment as a clinically relevant biomarker that may improve risk stratification and guide individualized therapy in geriatric oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.